Related Experiment Videos
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita1, Paolo de Fabritiis, Antonio Palumbo
1Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy. tcaravita@yahoo.it
Nature Clinical Practice. Oncology
|July 11, 2006
Summary
Proteasome inhibition, a novel anticancer strategy, shows promise in halting tumor progression. Bortezomib, a leading proteasome inhibitor, demonstrates significant antitumor activity and manageable toxicity in clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Proteasome inhibition is an emerging anticancer strategy.
- Bortezomib is the first clinically approved proteasome inhibitor.
- It targets tumor growth, metastasis, and angiogenesis via multiple mechanisms.
Purpose of the Study:
- To summarize clinical trials of bortezomib.
- To discuss its efficacy in various cancers.
- To highlight its role in cancer treatment.
Main Methods:
- Review of principal clinical trials.
- Analysis of bortezomib's efficacy data.
- Assessment of safety and tolerability.
Main Results:
- Bortezomib exhibits predictable, dose-related proteasome inhibition.
- Antitumor activity observed across various malignancies.
- Manageable nonhematologic and hematologic toxicity reported.
Conclusions:
- Bortezomib is an effective treatment for multiple myeloma.
- Its application is expanding to second-line treatment.
- Further research into its efficacy in solid and hematologic tumors is warranted.